BR112016001544A2 - composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas - Google Patents

composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas

Info

Publication number
BR112016001544A2
BR112016001544A2 BR112016001544A BR112016001544A BR112016001544A2 BR 112016001544 A2 BR112016001544 A2 BR 112016001544A2 BR 112016001544 A BR112016001544 A BR 112016001544A BR 112016001544 A BR112016001544 A BR 112016001544A BR 112016001544 A2 BR112016001544 A2 BR 112016001544A2
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical compositions
agents
pharmaceutical
antibacterial
Prior art date
Application number
BR112016001544A
Other languages
English (en)
Other versions
BR112016001544A8 (pt
Inventor
Covalesky Bernard
T Liegner Jeffery
Scott KAROLCHYK John
Peters Kallan
Dilzer Richard
Original Assignee
Eye Care Northwest Pa
Harrow Health Inc
Imprimis Pharmaceuticals Inc
Novel Drug Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50640013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016001544(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eye Care Northwest Pa, Harrow Health Inc, Imprimis Pharmaceuticals Inc, Novel Drug Solutions Llc filed Critical Eye Care Northwest Pa
Publication of BR112016001544A2 publication Critical patent/BR112016001544A2/pt
Publication of BR112016001544A8 publication Critical patent/BR112016001544A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas são descritas composições farmacêuticas para injeção intraocular, as composições consistindo essencialmente em uma quantidade terapeuticamente eficaz de um agente antibacteriano (por exemplo, moxifloxacina), uma quantidade terapeuticamente eficaz de um agente anti-inflamatório (por exemplo, triancinolona), pelo menos um excipiente farmaceuticamente aceitável e um carrea-dor farmaceuticamente aceitável. são também descritos métodos para fabricar as composições e a sua utilização para injeções intraoculares.
BR112016001544A 2013-07-22 2014-03-27 composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório BR112016001544A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361958170P 2013-07-22 2013-07-22
PCT/US2014/032026 WO2015012899A1 (en) 2013-07-22 2014-03-27 Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent

Publications (2)

Publication Number Publication Date
BR112016001544A2 true BR112016001544A2 (pt) 2017-07-25
BR112016001544A8 BR112016001544A8 (pt) 2021-08-03

Family

ID=50640013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016001544A BR112016001544A8 (pt) 2013-07-22 2014-03-27 composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório

Country Status (11)

Country Link
US (1) US20150024996A1 (pt)
EP (1) EP3024475B8 (pt)
JP (5) JP2016525544A (pt)
KR (1) KR20160033213A (pt)
AU (1) AU2014293665B2 (pt)
BR (1) BR112016001544A8 (pt)
CA (1) CA2919081C (pt)
HK (1) HK1223824A1 (pt)
IL (1) IL243750A0 (pt)
MX (1) MX2016000964A (pt)
WO (1) WO2015012899A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6682898B2 (ja) * 2016-02-17 2020-04-15 富士通株式会社 基地局、無線通信システムおよび基地局の処理方法
KR20190109604A (ko) * 2016-05-06 2019-09-25 해로우 헬스 인코포레이티드 약학적 안과용 조성물 및 그의 제조 방법
JP7101694B2 (ja) 2016-11-16 2022-07-15 ペルシカ ファーマシューティカルズ リミテッド 腰痛のための抗生物質製剤
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
US11510930B2 (en) 2020-08-26 2022-11-29 Somerset Therapeutics, Llc Gatifloxacin, prednisolone, and bromfenac compositions and methods
US11382910B2 (en) 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods
US11523987B2 (en) 2020-08-26 2022-12-13 Somerset Therapeutics, Llc Trimcinolone and moxifloxacin methods
EP4260844A1 (en) 2022-04-11 2023-10-18 Liegner, Jeffery T. Ophthalmological compositions comprising poloxamer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1192368A (ja) * 1997-07-23 1999-04-06 Ono Pharmaceut Co Ltd ベンゾピラン誘導体を主成分とする水性液剤
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
JP2003176228A (ja) * 2001-12-11 2003-06-24 Rohto Pharmaceut Co Ltd 液 剤
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
JP4968954B2 (ja) * 2005-05-10 2012-07-04 アルコン，インコーポレイテッド 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
US20080262415A1 (en) * 2005-07-18 2008-10-23 Peyman Gholam A Enhanced wound healing
WO2010068281A2 (en) * 2008-12-11 2010-06-17 Massachusetts Institute Of Technology Contact lens drug delivery device
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―，インク． ポロクサマーを包含する製剤のゲル化温度の調節
US20140127269A1 (en) * 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof

Also Published As

Publication number Publication date
JP7362870B2 (ja) 2023-10-17
NZ716208A (en) 2020-12-18
WO2015012899A1 (en) 2015-01-29
CA2919081C (en) 2021-11-16
AU2014293665B2 (en) 2017-06-01
JP2019167376A (ja) 2019-10-03
EP3024475B1 (en) 2020-09-30
JP2022185059A (ja) 2022-12-13
CA2919081A1 (en) 2015-01-29
IL243750A0 (en) 2016-04-21
EP3024475A1 (en) 2016-06-01
BR112016001544A8 (pt) 2021-08-03
JP2024001149A (ja) 2024-01-09
HK1223824A1 (zh) 2017-08-11
AU2014293665A1 (en) 2016-02-11
JP2021121608A (ja) 2021-08-26
EP3024475B8 (en) 2020-11-18
MX2016000964A (es) 2016-08-03
JP7232128B2 (ja) 2023-03-02
KR20160033213A (ko) 2016-03-25
JP2016525544A (ja) 2016-08-25
US20150024996A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
BR112019005046A2 (pt) combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
BR112016007328A2 (pt) composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas
IN2013MU03583A (pt)
CL2015002835A1 (es) Nuevos derivados de piridina
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
IN2013MU00711A (pt)
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EP3000464A3 (en) Composition comprising farnesol and use thereof
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112017015452A2 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: HARROW HEALTH, INC. (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: HARROW HEALTH, INC. (US)

Free format text: A FIM DE ATENDER A(S) TRANSFERENCIA(S), REQUERIDA(S) ATRAVES DA PETICAO NO 870200049634DE 20/04/2020, E NECESSARIO:1. QUE O DOCUMENTO QUE COMPROVA A TRANSFERENCIA ESTEJA ACOMPANHADO DA LEGALIZACAOCONSULAR OU DA APOSTILA DE HAIA. 2. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA.

B25B Requested transfer of rights rejected

Owner name: HARROW HEALTH, INC. (US)

B25A Requested transfer of rights approved

Owner name: NOVEL DRUG SOLUTIONS LLC (US) ; EYE CARE NORTHWEST, PA (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]